drugset
drugset / Trial / NCT04043065

Liver-enriched Antimicrobial Peptide 2

NCT04043065 ↗

Phase 0 Completed 10 enrolled University Hospital, Gentofte, Copenhagen Gubra ApS · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The investigators aim to investigate the physiological importance of LEAP-2 in healthy volunteers focusing on its potential insulinotropic effects.

Timeline

Start
2019-01-28
Primary completion
2019-05-20
Completion
2019-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Liver-enriched antimicrobial peptide 2 Peptide — Other

Indications

type 2 diabetes mellitus